Do Plaquenil or Hydroxychloroquine Require Eye Exams?

This question usually comes from people prescribed hydroxychloroquine for lupus, rheumatoid arthritis, or another autoimmune condition, who are told by their rheumatologist to see an eye doctor regularly and want to understand why. The medication controls their disease well and they feel fine, so being sent for eye testing when nothing seems wrong can be puzzling. Many have heard the word toxicity and want to know how likely the risk really is and what the exams are looking for.

Hydroxychloroquine can, over years, accumulate in and damage the macula, the small central part of the retina responsible for sharp reading and detail vision. Early on, this produces no symptoms at all; the sensitive central vision can be affected in a ring-shaped pattern around the very center before you would ever notice. If use continues after damage begins, it can spread and eventually blunt central vision permanently.

That combination, serious but silent early, is exactly why monitoring exists. Waiting for symptoms means waiting until damage is already advanced. By testing the retina and central visual field on a schedule, your doctor can spot the earliest signs while your vision is still normal, so the medication can be stopped or changed before your sight is affected.

Retinal toxicity from hydroxychloroquine is dose- and duration-related. The most important factor is the daily dose relative to body weight, and risk climbs substantially with cumulative use over many years, particularly beyond about five years. Impaired kidney function raises risk because it slows clearance of the drug, and taking tamoxifen or having pre-existing macular disease also increases susceptibility. So the prescribing physician chooses a weight-based dose, and the eye doctor tailors screening to your individual risk.

The recommended approach is a baseline examination near the time you start, ideally within the first year, to document the healthy retina and rule out any pre-existing macular problem. If your risk is average, annual screening typically begins after five years of use; if you have added risk factors, it starts sooner. This general framework follows longstanding ophthalmology guidance, and your own schedule should be set by your eye doctor. Screening does not rely on symptoms: the mainstays are OCT imaging, which can reveal early thinning of the retinal layers, and an automated visual field test focused on central vision, which can detect subtle sensitivity loss. Together these are sensitive enough to catch toxicity when stopping the drug can still prevent meaningful vision loss.

Established hydroxychloroquine retinal toxicity is serious precisely because it is permanent, which is why the emphasis is on catching it before symptoms. Warning signs that damage may already be present include trouble reading, missing letters or small blank spots in your central vision, or colors appearing washed out; these should prompt a prompt eye evaluation rather than waiting for the next scheduled screening. Any new central vision change while on this medication deserves attention. The screening schedule is the safeguard that keeps a rare complication from becoming a sight-threatening one.

Screening centers on the two most sensitive tests for this toxicity: OCT imaging of the macula, which can show early structural thinning, and an automated visual field test targeting central vision, which can pick up early functional loss. Your ophthalmologist establishes a baseline at the start, examines the macula directly, and repeats these tests on the schedule matched to your risk. When results are borderline, additional retinal imaging may confirm. Your doctor also reviews your dose, weight, kidney function, and years of use to gauge your individual risk and coordinates findings with your prescribing rheumatologist.

There is no medication that reverses hydroxychloroquine retinal toxicity, so management is about prevention and early detection. The most important protective measures are correct weight-based dosing set by your prescriber and adherence to the recommended baseline and screening exams. If screening detects early toxicity, the decisive step is to stop the medication, in coordination with the doctor treating your autoimmune condition, so further damage is prevented; the rheumatologist can usually substitute an alternative treatment. Because existing damage tends to be permanent, halting the drug early is the treatment that preserves the most vision, which is why timely screening is so valuable.

• Do not skip your baseline or annual screening exams because you feel fine; early toxicity is completely silent.
• Do not take more than your prescribed dose or share the medication, since risk is closely tied to daily dose relative to body weight.
• Do not stop hydroxychloroquine on your own out of fear; any change should be coordinated with the doctor managing your autoimmune disease.
• Do not ignore new reading difficulty, small blank spots, or faded colors in your central vision; have those checked promptly.

Call to set up your baseline exam when you start hydroxychloroquine, and to keep your recommended screening exams on schedule thereafter. Reach out sooner if you notice new trouble reading, small gaps in your central vision, or washed-out colors. May Eye Care Center provides baseline and ongoing Plaquenil screening with OCT and visual field testing for patients across the Hanover, Pennsylvania area and can coordinate with your rheumatologist.

Hydroxychloroquine (Plaquenil) does require regular eye exams: a baseline at the start and periodic screening with OCT and visual field testing, because these catch its rare but permanent retinal toxicity early, while your vision can still be protected.